Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29944898 | 1.00 | TSHR (0.56) | TSHRGAAPOLBGLACYP3A4 | |
| Hydrochloric Acid SCHEMBL14935577 | 0.98 | TSHR (0.54) | TSHRGAAPOLBGLACYP3A4 | |
| SCHEMBL5958773 | 0.83 | CYP3A4 (0.48) | TSHRGAAPOLBGLACYP3A4 | |
| SCHEMBL29938047 | 0.83 | CYP3A4 (0.48) | TSHRGAAPOLBGLACYP3A4 | |
| SCHEMBL30574189 | 0.82 | TSHR (0.61) | TSHRGAAPOLBGLACYP3A4 | |
| SCHEMBL203216 | 0.82 | TSHR (0.61) | TSHRGAAPOLBGLACYP3A4 | |
| Hydrochloric Acid SCHEMBL4383138 | 0.80 | TSHR (0.59) | TSHRGAAPOLBGLACYP3A4 | |
| Fluoride SCHEMBL10883445 | 0.80 | TSHR (0.59) | TSHRGAAPOLBGLACYP3A4 | |
| Hydrochloric Acid SCHEMBL9827180 | 0.80 | TSHR (0.59) | TSHRGAAPOLBGLACYP3A4 | |
| SCHEMBL31078134 | 0.79 | CA1 (0.45) | TSHRGAAPOLBGLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433093-A | Preparation method of 3-chloro-4-trifluoromethylaniline | 无锡双启科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-113874372-A | Novel oxadiazole compounds for controlling or preventing phytopathogenic fungi | PI工业有限公司 | 2021-12-31 | — | — | CN | claimed |
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | claimed |
| EP-2486042-B1 | BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-22 | — | — | EP | claimed |
| US-8471004-B2 | Bicyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-8445674-B2 | Heterocyclyl compounds | Hoffmann-La Roche Inc (US) | 2013-05-21 | — | — | US | claimed |
| EP-2491022-A1 | DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2012-08-29 | — | — | EP | claimed |
| EP-2486042-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-15 | — | — | EP | claimed |
| JP-5065258-A | — | — | None | — | — | JP | disclosed |
| EP-4161642-B1 | N-PHENYLAMINOCARBONYL PYRIDINO- , PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | PATHIOS THERAPEUTICS LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| CN-122029167-A | Condensed heteroaryl compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| US-12357615-B2 | Compositions for the treatment of brain tumors | KEMBI THERAPEUTICS PTY LTD (AU) | 2025-07-15 | — | — | US | disclosed |
| EP-0012435-A2 | Isoxazole derivatives, process for their preparation, medicines containing them and intermediates required in this process | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-06-25 | — | — | EP | disclosed |
| EP-0008435-A2 | Substituted N-phenyl-N'-benzoyl-thioureas, their preparation and their use as pesticides | BAYER AG (DE) | 1980-03-05 | — | — | EP | disclosed |
| US-4183949-A | Pesticidally active 1-arylamino-2,4-dinitronaphthalenes | BAYER AKTIENGESELLSCHAFT (DE) | 1980-01-15 | — | — | US | disclosed |
| EP-0004642-A1 | Diaryl amines, process for their preparation and their use | BAYER AG (DE) | 1979-10-17 | — | — | EP | disclosed |
| US-4162329-A | Combating fungi with dicarboxylic acid mono-arylhydrazides | BAYER AKTIENGESELLSCHAFT (DE) | 1979-07-24 | — | — | US | disclosed |
| US-3975534-A | Pharmaceutical compositions useful for treating tick infestation in animals which contain 2-aryliminopyrrolidines or their salts as the active agent | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | TSHR 4098/4885GAA 4408/4885POLB 4641/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | TSHR 37/4885GAA 633/4885POLB 2709/4885 |
| US-12357615-B2 | Compositions for the treatment of brain tumors | NR3C2, NR3C1, CRH | TSHR 161/4885GAA 2009/4885POLB 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.